[HTML][HTML] The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - frontiersin.org
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - europepmc.org
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
[HTML][HTML] The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - ncbi.nlm.nih.gov
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
[HTML][HTML] The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - frontiersin.org
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - cir.nii.ac.jp
抄録< jats: p> Lu-177 has been developed for the treatment of patients with peptide receptor
radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high …
radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high …
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in endocrinology, 2022 - pubmed.ncbi.nlm.nih.gov
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - europepmc.org
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …